Cytovance Biologics

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and hemostasis research and diagnostics. Our products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize line of complete ELISA kits, and a full line of human plasma products including VisuDep Immune-Depleted Factor-Deficient Plasmas, VisuCal Calibrator Plasma and VisuCon Control Plasmas. Services include protein purification, antibody production, assay development, custom manufacturing including custom lyophilization and proficiency testing materials.

For more information please visit www.affinitybiologicals.com.

Avitide discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products. Avitide has successfully deployed affinity purification technologies towards an array of biological molecules including enzymes, bispecific antibodies, therapeutic scaffolds, growth factors, hormones, insulins, blood factors, Fcfusions, cell-based therapies, vaccines, and gene therapy viral vectors. Avitide's management team brings substantial industry expertise and a successful track record in commercializing innovative biopharmaceutical manufacturing platforms. Avitide is financed by premier venture capital and private equity firms, including Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, Sands
Capital Ventures, Section 32, SV Health Investors, Borealis Ventures, and NeoMed Management. For more information, visit www.avitide.com.

Since its founding in 1992, bioWORLD has established, maintained, and succeeded in its core mission to manufacture and supply high-quality molecular tools, biological reagents, and laboratory supplies to analytical laboratories, academia institutions, and research corporations globally. bioWORLD specializes in numerous product lines for the Life Sciences and Biotechnology industries. With product focuses including bioAffinity reagents for protein purification and proteomics research, recombinant proteins and synthetic peptides, plant, microbiological, animal, and yeast media, and many other fields. In addition, bioWORLD offers services including custom peptide synthesis and antibody production.

The company's headquarters are in Dublin, Ohio, with sales offices located across the globe. Through both in-house manufacturing and supply chain acquisitions, bioWORLD supplies products to biomedical and life sciences industries. In addition, we provide custom laboratory services and formulations for R&D in the biotechnology industry. bioWORLD is a growing company, with both domestic channel partners (i.e. Fisher Scientific, Spectrum Chemical, Thomas Scientific, etc.) as well as established international distribution partners in 45 countries.

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.
In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.
Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease.
In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.

Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).

Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.

In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.

Clara Diagnostics is developing the Exosome Sorting System (ExoSS), a high-throughput microfluidic system for the isolation and purification of exosomes. The company aims to launch the first microfluidic exosome sorting device (ExoSS) into the marketplace for automated, high-specificity, and high throughput preparation of exact exosome subtypes from a variety of biofluids.
The ExoSS system performs isolation 100x faster than ultracentrifugation and able to extract greater than 90% of exosomes with an isolation purity greater than 90%. ExoSS rapidly runs parallel samples continuously, resulting in a platform ideal for large volume processing. Designed for low skill automation, ExoSS has the advantage of extracting all or only specific
types of exosomes from the biological source.
An On Site Non-Clinical Isolation Service (ExoSS OnSite) was launched in November 2018 by the company utilizing the existing ExoSS system.
Clara Diagnostics is focused on establishing strategic partnerships for development in diagnostic and therapeutic applications, equipment manufacturing, antibody sourcing, distribution, sales and marketing.